About POU domain, class 4, transcription factor 2
POU domain, class 4, transcription factor 2 (POU4F2) is a protein
from Homo sapiens identified by UniProt accession
Q12837, 409 residues long.
MolForge cross-references it against 0 known binders and
176 disease associations.
Target properties
| Protein name | POU domain, class 4, transcription factor 2 |
| UniProt accession | Q12837 |
| Gene | POU4F2 |
| Organism | Homo sapiens |
| Length | 409 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (176)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.48
- breast adenocarcinoma · score 0.25
- glioblastoma multiforme · score 0.25
- lung adenocarcinoma · score 0.19
- esophageal cancer · score 0.18
- squamous cell lung carcinoma · score 0.18
- gastric adenocarcinoma · score 0.18
- urinary bladder cancer · score 0.18
- head and neck squamous cell carcinoma · score 0.18
- endometrial cancer · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q12837-F1 | alphafold | PREDICTED | 61.79 | — |
Amino-acid sequence (409 residues)
MMMMSLNSKQ AFSMPHGGSL HVEPKYSALH STSPGSSAPI APSASSPSSS SNAGGGGGGG GGGGGGGGRS SSSSSSGSSG GGGSEAMRRA CLPTPPSNIF GGLDESLLAR AEALAAVDIV SQSKSHHHHP PHHSPFKPDA TYHTMNTIPC TSAASSSSVP ISHPSALAGT HHHHHHHHHH HHQPHQALEG ELLEHLSPGL ALGAMAGPDG AVVSTPAHAP HMATMNPMHQ AALSMAHAHG LPSHMGCMSD VDADPRDLEA FAERFKQRRI KLGVTQADVG SALANLKIPG VGSLSQSTIC RFESLTLSHN NMIALKPILQ AWLEEAEKSH REKLTKPELF NGAEKKRKRT SIAAPEKRSL EAYFAIQPRP SSEKIAAIAE KLDLKKNVVR VWFCNQRQKQ KRMKYSAGI
Explore POU domain, class 4, transcription factor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets